Ten Hoorn, Sanne; Waasdorp, Cynthia; van Oijen, Martijn G H; Damhofer, Helene; Trinh, Anne; Zhao, Lan; Smits, Lisanne J H; Bootsma, Sanne; van Pelt, Gabi W; Mesker, Wilma E; Mol, Linda; Goey, Kaitlyn K H; Koopman, Miriam; Medema, Jan Paul; Tuynman, Jurriaan B; Zlobec, Inti; Punt, Cornelis J A; Vermeulen, Louis; Bijlsma, Maarten F (2022). Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. BMC cancer, 22(1), p. 394. BioMed Central 10.1186/s12885-022-09436-0 ten Hoorn, S, Waasdorp, C, van Oijen, M G H, Damhofer, H, Trinh, A, Zhao, L, Smits, L J H, Bootsma, S, van Pelt, G W, Mesker, W E, Mol, L, Goey, K K H, Koopman, M, Medema, J P, Tuynman, J B, Zlobec, I, Punt, C J A, Vermeulen, L & Bijlsma, M F 2022, ' Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer ', BMC Cancer, vol. 22, no. 1, 394 . https://doi.org/10.1186/s12885-022-09436-0 BMC cancer, 22(1):394. BioMed Central BMC Cancer, 22(1). BMC BMC Cancer, 22(1):394. BioMed Central